COPD EXACERBATIONS
COPD, which includes chronic bronchitis and emphysema, affects more than 24 million Americans and is the third leading cause of death in the U.S.
Centers for Disease ControlBOOSTING THE INNATE IMMUNE SYSTEM
Even with current vaccines, anti-virals and antibiotics significant unmet needs remain to better prevent and treat respiratory infections. Pulmotect technology has demonstrated activity and completed Phase I clinical trials to address these unmet needs.
PULMOTECT, INC. is a bio-pharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.
EPIDEMIC AND EMERGING PATHOGENS
More than 2 billion people worldwide could be impacted by a pandemic. Despite remarkable advances in medical research and treatments during the 20th century, infectious diseases remain among the leading causes of death worldwide.
National Institute of Allergy and Infectious Disease
IMMUNOCOMPROMISED PATIENTS
Forecast sales for the immuno-stimulants market are estimated to reach $17.6 billion.
The Cancer Market Outlook: Competitive landscape, pipeline analysis and growth opportunitiesOur Product
Pulmotect’s lead product, PUL-042, is a clinically stage inhaled therapeutic that stimulates the innate immune system in minutes to provide immediate and effective protection that lasts for days against all major classes of pathogens.
Our Research
Two previously completed phase I clinical trials tested PUL-042’s safety and patient tolerance in healthy individuals, which showed an acceptable safety profile. Armed with FDA approval to begin a third trial, researchers are set to conduct a follow-up dosing study to establish the drug’s efficacy in stable, but immune-compromised cancer patients.
The Market
Pulmotect’s initial market focus is on the reduction of chronic obstructive pulmonary disease (COPD) exacerbations, which are characterized by an acute worsening of symptoms mostly precipitated by a bacterial or viral infection.